Linghong Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linghong Huang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Jun Long
Department of Urology, Guangdong Provincial Key Laboratory of Urological Diseases, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, the First Affiliated Hospital of Guangzhou Medical University
5 shared publications- Xin-Yuan Sun
Department of Urology, Guangzhou Institute of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510230, China
5 shared publications Zonghua Liu
4 shared publicationsJiansheng Lin
3 shared publicationsTing Song
3 shared publicationsXue-Wu Chen
Department of Urology, Guangdong Provincial Key Laboratory of Urological Diseases, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, the First Affiliated Hospital of Guangzhou Medical University
3 shared publications
Latest Publications
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (20) , 14488-14513
Mitochondria-Targeted Metal Polyphenol Networks Inhibit Crystalline Nephropathy by Modulating SerpinE1 and Remodeling the Pathological Mineralization Microenvironment
Crystalline nephropathy is driven by a self-perpetuating cycle in which crystal-induced tubular injury promotes further nucleation, growth, and aggregation, transforming the kidney into a pathological mineralization niche. Conventional therapies fail to disrupt this vicious loop, while nanomedicines are hindered by the glomerular filtration barrier (3+ coordination and functionalized with triphenylphosphonium (TPP), Fe-PCA@TPP efficiently traverses the glomerular barrier, accumulates selectively in mitochondria, scavenges free radicals broadly, restores redox homeostasis, and potently inhibits calcium oxalate (CaOx) crystal nucleation, growth, and aggregation. In vitro, Fe-PCA@TPP protects renal tubular epithelial cells from oxalate-induced oxidative stress by preserving mitochondrial bioenergetics and preventing apoptosis. In vivo, it preferentially accumulates in the kidney, reduces CaOx deposition, improves renal function, and downregulates markers of injury and inflammation. Mechanistically, Fe-PCA@TPP targets Plasminogen Activator Inhibitor Type 1 (SerpinE1) to block oxidative stress-apoptosis cascades, thereby remodeling the intrarenal pathological microenvironment. This work presents a size-compatible, mitochondria-targeted, and SerpinE1-specific nanoplatform that integrates crystal inhibition, redox regulation, and efficient renal clearance, offering a promising therapeutic strategy for crystalline nephropathy.
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (20) , 14488-14513
Mitochondria-Targeted Metal Polyphenol Networks Inhibit Crystalline Nephropathy by Modulating SerpinE1 and Remodeling the Pathological Mineralization Microenvironment
Crystalline nephropathy is driven by a self-perpetuating cycle in which crystal-induced tubular injury promotes further nucleation, growth, and aggregation, transforming the kidney into a pathological mineralization niche. Conventional therapies fail to disrupt this vicious loop, while nanomedicines are hindered by the glomerular filtration barrier (3+ coordination and functionalized with triphenylphosphonium (TPP), Fe-PCA@TPP efficiently traverses the glomerular barrier, accumulates selectively in mitochondria, scavenges free radicals broadly, restores redox homeostasis, and potently inhibits calcium oxalate (CaOx) crystal nucleation, growth, and aggregation. In vitro, Fe-PCA@TPP protects renal tubular epithelial cells from oxalate-induced oxidative stress by preserving mitochondrial bioenergetics and preventing apoptosis. In vivo, it preferentially accumulates in the kidney, reduces CaOx deposition, improves renal function, and downregulates markers of injury and inflammation. Mechanistically, Fe-PCA@TPP targets Plasminogen Activator Inhibitor Type 1 (SerpinE1) to block oxidative stress-apoptosis cascades, thereby remodeling the intrarenal pathological microenvironment. This work presents a size-compatible, mitochondria-targeted, and SerpinE1-specific nanoplatform that integrates crystal inhibition, redox regulation, and efficient renal clearance, offering a promising therapeutic strategy for crystalline nephropathy.
- 18 November 2025
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 222
Sodium hexametaphosphate mitigates calcium oxalate stone formation by modulating crystallization and maintaining PPARα signaling
Kidney stones are common diseases in the urinary system, characterized by high morbidity and recurrence rates, but effective drug treatments are limited. We chose sodium hexametaphosphate (HMP) to investigate its role in inhibiting calcium oxalate (CaOx) crystallization in vitro and in vivo. We predicted potential targets of HMP using bioinformatics, simulated drug molecular docking, and explored the molecular mechanism of HMP inhibition of CaOx stone formation in a cellular model and hyperoxaluria-induced crystallization rat model. HMP specifically adsorbed on high-energy crystal surfaces, inhibiting the growth of CaOx monohydrate (COM), significantly reducing crystal size, and promoting the conversion to CaOx dihydrate (COD). At higher concentrations, CaOx crystals transformed from micrometer to nanometer scale, achieving complete conversion from COM to COD and almost complete inhibition of CaOx crystal formation. Additionally, HMP significantly reduced oxidative damage caused by high oxalate in NRK-52E cells, decreased reactive oxygen species production, inhibited mitochondrial membrane potential depolarization, and subsequently inhibited cell apoptosis. By integrating the transcriptomic data and the crystallization results, HMP primarily acts by modulating CaOx crystallization, upregulating PPARα to promote fatty-acid transport and β-oxidation, thereby enhancing the expression of downstream antioxidant factors NRF2 and SOD1 and, in turn, attenuating hyperoxaluria-induced renal oxidative injury. The novel drug HMP, combining CaOx crystallization modulation and oxidative stress inhibition, may be a treatment option for kidney stones.
- 18 November 2025
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 222
Sodium hexametaphosphate mitigates calcium oxalate stone formation by modulating crystallization and maintaining PPARα signaling
Kidney stones are common diseases in the urinary system, characterized by high morbidity and recurrence rates, but effective drug treatments are limited. We chose sodium hexametaphosphate (HMP) to investigate its role in inhibiting calcium oxalate (CaOx) crystallization in vitro and in vivo. We predicted potential targets of HMP using bioinformatics, simulated drug molecular docking, and explored the molecular mechanism of HMP inhibition of CaOx stone formation in a cellular model and hyperoxaluria-induced crystallization rat model. HMP specifically adsorbed on high-energy crystal surfaces, inhibiting the growth of CaOx monohydrate (COM), significantly reducing crystal size, and promoting the conversion to CaOx dihydrate (COD). At higher concentrations, CaOx crystals transformed from micrometer to nanometer scale, achieving complete conversion from COM to COD and almost complete inhibition of CaOx crystal formation. Additionally, HMP significantly reduced oxidative damage caused by high oxalate in NRK-52E cells, decreased reactive oxygen species production, inhibited mitochondrial membrane potential depolarization, and subsequently inhibited cell apoptosis. By integrating the transcriptomic data and the crystallization results, HMP primarily acts by modulating CaOx crystallization, upregulating PPARα to promote fatty-acid transport and β-oxidation, thereby enhancing the expression of downstream antioxidant factors NRF2 and SOD1 and, in turn, attenuating hyperoxaluria-induced renal oxidative injury. The novel drug HMP, combining CaOx crystallization modulation and oxidative stress inhibition, may be a treatment option for kidney stones.
- 3 March 2025
- Published by Elsevier in Biomaterials
- Vol. 320, 123236
Mucus-penetrating nanomotor system strengthens mucosal immune response to in situ bacterial vaccine against severe bacterial pneumonia
- 3 March 2025
- Published by Elsevier in Biomaterials
- Vol. 320, 123236
Mucus-penetrating nanomotor system strengthens mucosal immune response to in situ bacterial vaccine against severe bacterial pneumonia
- 6 February 2025
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 13 (6) , 1512-1528
Sulfated Undaria pinnatifida polysaccharides inhibit kidney stone formation through crystalline modulation and relieving cellular oxidative damage and inflammation
Background: Calcium oxalate (CaOx) crystal deposition and its resultant cellular oxidative damage and inflammation are important causes of renal stone formation. It is clinically important to conduct research on multifunctional anti-stone drugs targeting these predisposing factors. Methods: We modified natural Undaria pinnatifida polysaccharide (UPP0) by sulfation via the sulfur trioxide-pyridine method, resulting in four sulfated polysaccharides with varying sulfate group (–OSO3 −) contents: 1.59% (UPP0), 6.03% (UPP1), 20.83% (UPP2), and 36.39% (UPP3), and compared their differences in the inhibition of crystalline formation, renal injury, and inflammation in the process of renal stone formation at chemical and cellular levels. Results: The UPPS were able to inhibit the nucleation, growth and aggregation of CaOx crystals in vitro. Among them, UPP3 with the maximum sulfate group content showed the greatest crystallization inhibition ability. The nucleation inhibition and aggregation inhibition of UPP3 at a concentration of 0.5 mg mL−1 were as high as 80.21% and 72.34%, respectively. The CaOx crystal size regulated by UPP3 was significantly reduced from 25.9 ± 2.8 μm to 5.9 ± 1.2 μm. Furthermore, UPPS were observed to up-regulate the expression of the antioxidant enzyme superoxide dismutase (SOD) in cells, reduce the levels of ROS and malonaldehyde (MDA), enhance lysosomal integrity, decrease intracellular Ca2+ levels, inhibit the decline in mitochondrial membrane potential, reduce the production of cellular inflammatory factors (TNF-α, MCP-1, IL-18, and IL-1β), and ultimately inhibit cell apoptosis. Conclusion: UPPS combine multiple biological functions of crystallization regulation, antioxidant and anti-inflammatory, and have important potential in the prevention of kidney stones. Sulfation modification can improve the biological activity of UPP0 and provide a reference for screening and optimization methods of stone drugs.
- 6 February 2025
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 13 (6) , 1512-1528
Sulfated Undaria pinnatifida polysaccharides inhibit kidney stone formation through crystalline modulation and relieving cellular oxidative damage and inflammation
Background: Calcium oxalate (CaOx) crystal deposition and its resultant cellular oxidative damage and inflammation are important causes of renal stone formation. It is clinically important to conduct research on multifunctional anti-stone drugs targeting these predisposing factors. Methods: We modified natural Undaria pinnatifida polysaccharide (UPP0) by sulfation via the sulfur trioxide-pyridine method, resulting in four sulfated polysaccharides with varying sulfate group (–OSO3 −) contents: 1.59% (UPP0), 6.03% (UPP1), 20.83% (UPP2), and 36.39% (UPP3), and compared their differences in the inhibition of crystalline formation, renal injury, and inflammation in the process of renal stone formation at chemical and cellular levels. Results: The UPPS were able to inhibit the nucleation, growth and aggregation of CaOx crystals in vitro. Among them, UPP3 with the maximum sulfate group content showed the greatest crystallization inhibition ability. The nucleation inhibition and aggregation inhibition of UPP3 at a concentration of 0.5 mg mL−1 were as high as 80.21% and 72.34%, respectively. The CaOx crystal size regulated by UPP3 was significantly reduced from 25.9 ± 2.8 μm to 5.9 ± 1.2 μm. Furthermore, UPPS were observed to up-regulate the expression of the antioxidant enzyme superoxide dismutase (SOD) in cells, reduce the levels of ROS and malonaldehyde (MDA), enhance lysosomal integrity, decrease intracellular Ca2+ levels, inhibit the decline in mitochondrial membrane potential, reduce the production of cellular inflammatory factors (TNF-α, MCP-1, IL-18, and IL-1β), and ultimately inhibit cell apoptosis. Conclusion: UPPS combine multiple biological functions of crystallization regulation, antioxidant and anti-inflammatory, and have important potential in the prevention of kidney stones. Sulfation modification can improve the biological activity of UPP0 and provide a reference for screening and optimization methods of stone drugs.
- Open Access
- 24 January 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101523
A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
- 24 January 2025
- Published by Elsevier in Materials Today Bio
- Vol. 31, 101523
Open AccessA pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
- Open Access
- 17 June 2024
- Published by Elsevier in Journal of Functional Foods
- Vol. 119
Hydroxycitric acid inhibits ectopic calcification of renal interstitial fibroblasts by suppressing cell apoptosis
- 17 June 2024
- Published by Elsevier in Journal of Functional Foods
- Vol. 119
Open AccessHydroxycitric acid inhibits ectopic calcification of renal interstitial fibroblasts by suppressing cell apoptosis
- Open Access
- 8 May 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-17
Construction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response
Tumor vaccines, a crucial immunotherapy, have gained growing interest because of their unique capability to initiate precise anti-tumor immune responses and establish enduring immune memory. Injected tumor vaccines passively diffuse to the adjacent draining lymph nodes, where the residing antigen-presenting cells capture and present tumor antigens to T cells. This process represents the initial phase of the immune response to the tumor vaccines and constitutes a pivotal determinant of their effectiveness. Nevertheless, the granularity paradox, arising from the different requirements between the passive targeting delivery of tumor vaccines to lymph nodes and the uptake by antigen-presenting cells, diminishes the efficacy of lymph node-targeting tumor vaccines. This study addressed this challenge by employing a vaccine formulation with a tunable, controlled particle size. Manganese dioxide (MnO2) nanoparticles were synthesized, loaded with ovalbumin (OVA), and modified with A50 or T20 DNA single strands to obtain MnO2/OVA/A50 and MnO2/OVA/T20, respectively. Administering the vaccines sequentially, upon reaching the lymph nodes, the two vaccines converge and simultaneously aggregate into MnO2/OVA/A50-T20 particles through base pairing. This process enhances both vaccine uptake and antigen delivery. In vitro and in vivo studies demonstrated that, the combined vaccine, comprising MnO2/OVA/A50 and MnO2/OVA/T20, exhibited robust immunization effects and remarkable anti-tumor efficacy in the melanoma animal models. The strategy of controlling tumor vaccine size and consequently improving tumor antigen presentation efficiency and vaccine efficacy via the DNA base-pairing principle, provides novel concepts for the development of efficient tumor vaccines. Graphical Abstract
- 8 May 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-17
Open AccessConstruction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response
Tumor vaccines, a crucial immunotherapy, have gained growing interest because of their unique capability to initiate precise anti-tumor immune responses and establish enduring immune memory. Injected tumor vaccines passively diffuse to the adjacent draining lymph nodes, where the residing antigen-presenting cells capture and present tumor antigens to T cells. This process represents the initial phase of the immune response to the tumor vaccines and constitutes a pivotal determinant of their effectiveness. Nevertheless, the granularity paradox, arising from the different requirements between the passive targeting delivery of tumor vaccines to lymph nodes and the uptake by antigen-presenting cells, diminishes the efficacy of lymph node-targeting tumor vaccines. This study addressed this challenge by employing a vaccine formulation with a tunable, controlled particle size. Manganese dioxide (MnO2) nanoparticles were synthesized, loaded with ovalbumin (OVA), and modified with A50 or T20 DNA single strands to obtain MnO2/OVA/A50 and MnO2/OVA/T20, respectively. Administering the vaccines sequentially, upon reaching the lymph nodes, the two vaccines converge and simultaneously aggregate into MnO2/OVA/A50-T20 particles through base pairing. This process enhances both vaccine uptake and antigen delivery. In vitro and in vivo studies demonstrated that, the combined vaccine, comprising MnO2/OVA/A50 and MnO2/OVA/T20, exhibited robust immunization effects and remarkable anti-tumor efficacy in the melanoma animal models. The strategy of controlling tumor vaccine size and consequently improving tumor antigen presentation efficiency and vaccine efficacy via the DNA base-pairing principle, provides novel concepts for the development of efficient tumor vaccines. Graphical Abstract
- Top Cited Papers
- 29 April 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (19) , 12261-12275
Light-Triggered Nanozymes Remodel the Tumor Hypoxic and Immunosuppressive Microenvironment for Ferroptosis-Enhanced Antitumor Immunity
Cancer immunotherapy holds significant promise for addressing diverse malignancies. Nevertheless, its efficacy remains constrained by the intricate tumor immunosuppressive microenvironment. Herein, a light-triggered nanozyme Fe-TCPP-R848-PEG (Fe-MOF-RP) was designed for remodeling the immunosuppressive microenvironment. The Fe-TCPP-MOFs were utilized not only as a core catalysis component against tumor destruction but also as a biocompatible delivery vector of an immunologic agonist, improving its long circulation and tumor enrichment. Concurrently, it catalyzes the decomposition of H2O2 within the tumor, yielding oxygen to augment photodynamic therapy. The induced ferroptosis, in synergy with photodynamic therapy, prompts the liberation of tumor-associated antigens from tumor cells inducing immunogenic cell death. Phototriggered on-demand release of R848 agonists stimulated the maturation of dendritic cells and reverted the tumor-promoting M2 phenotypes into adoptive M1 macrophages, which further reshaped the tumor immunosuppressive microenvironment. Notably, the nanozyme effectively restrains well-established tumors, such as B16F10 melanoma. Moreover, it demonstrates a distal tumor-inhibiting effect upon in situ light treatment. What is more, in a lung metastasis model, it elicits robust immune memory, conferring enduring protection against tumor rechallenge. Our study presents a straightforward and broadly applicable strategy for crafting nanozymes with the potential to effectively thwart cancer recurrence and metastasis.
- 29 April 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (19) , 12261-12275
Top Cited PapersLight-Triggered Nanozymes Remodel the Tumor Hypoxic and Immunosuppressive Microenvironment for Ferroptosis-Enhanced Antitumor Immunity
Cancer immunotherapy holds significant promise for addressing diverse malignancies. Nevertheless, its efficacy remains constrained by the intricate tumor immunosuppressive microenvironment. Herein, a light-triggered nanozyme Fe-TCPP-R848-PEG (Fe-MOF-RP) was designed for remodeling the immunosuppressive microenvironment. The Fe-TCPP-MOFs were utilized not only as a core catalysis component against tumor destruction but also as a biocompatible delivery vector of an immunologic agonist, improving its long circulation and tumor enrichment. Concurrently, it catalyzes the decomposition of H2O2 within the tumor, yielding oxygen to augment photodynamic therapy. The induced ferroptosis, in synergy with photodynamic therapy, prompts the liberation of tumor-associated antigens from tumor cells inducing immunogenic cell death. Phototriggered on-demand release of R848 agonists stimulated the maturation of dendritic cells and reverted the tumor-promoting M2 phenotypes into adoptive M1 macrophages, which further reshaped the tumor immunosuppressive microenvironment. Notably, the nanozyme effectively restrains well-established tumors, such as B16F10 melanoma. Moreover, it demonstrates a distal tumor-inhibiting effect upon in situ light treatment. What is more, in a lung metastasis model, it elicits robust immune memory, conferring enduring protection against tumor rechallenge. Our study presents a straightforward and broadly applicable strategy for crafting nanozymes with the potential to effectively thwart cancer recurrence and metastasis.